About this Journal Submit a Manuscript Table of Contents
Volume 2010 (2010), Article ID 130646, 9 pages
Review Article

Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases

1EA2216 Immunology and Pathology and IFR 148 ScInBioS, European University of Brittany, BP 824, 29609 Brest, France
2Experimental Immunotherapy Department, Center for Molecular Immunology, P.O. Box 16040, 11600 La Havana, Cuba
3Laboratory of Immunology, CHU Brest, Brest University Medical School Hospital, BP 824, 29609 Brest, France

Received 16 August 2010; Accepted 22 December 2010

Academic Editor: Deh-Ming Chang

Copyright © 2010 Ruby Alonso-Ramirez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [5 citations]

The following is the list of published articles that have cited the current article.

  • Mafalda Pinto, and Alexandre M. Carmo, “CD6 as a Therapeutic Target in Autoimmune Diseases: Successes and Challenges,” Biodrugs, vol. 27, no. 3, pp. 191–202, 2013. View at Publisher · View at Google Scholar
  • Christelle Dantec, Ruby Alonso, Tinhinane Fali, Enrique Montero, Valérie Devauchelle, Alain Saraux, Jacques-Olivier Pers, and Yves Renaudineau, “Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab),” Immunologic Research, 2013. View at Publisher · View at Google Scholar
  • M. Wagner, M. Bilinska, A. Pokryszko–Dragan, M. Sobczynski, M. Cyrul, P. Kusnierczyk, and M. Jasek, “ALCAM and CD6 – multiple sclerosis risk factors,” Journal of Neuroimmunology, 2014. View at Publisher · View at Google Scholar
  • Lazaro E. Aira, Alejandro Lopez-Requena, Dasha Fuentes, Liset Sanchez, Teresita Perez, Aleida Urquiza, Heber Bautista, Leopoldina Falcon, Patricia Hernandez, and Zaima Mazorra, “Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab,” Mabs, vol. 6, no. 3, pp. 782–792, 2014. View at Publisher · View at Google Scholar
  • D.S. Krupashankar, Sunil Dogra, Mahendra Kura, Abir Saraswat, Leelavathy Budamakuntla, T.K. Sumathy, Radha Shah, M.G. Gopal, T. Narayana Rao, Enrique Montero, M.S. Ramakrishnan, Pradip Nair, and Prasanna C. Ganapathi, “Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study,” Journal of the American Academy of Dermatology, 2014. View at Publisher · View at Google Scholar